ROS1 and non-small cell lung carcinoma: Despite the limited number of ROS1+ glioblastoma with OS survival information(N = 9), ROS1+ GBM patients had overall approximately 6 months (170 days) shorter OS while there was no major the differences between ROS1+ NSCLC versus non-ROS1+ NSCLC.